Status:
UNKNOWN
Safety and Performance Study of Large Hole Vascular Closure Device - France
Lead Sponsor:
Vivasure Medical Limited
Conditions:
Large Hole Percutaneous Arterial Closure
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This study will be a prospective, multi-centred, non-randomized study to investigate the safety and performance of the PerQseal® + in up to 20 patients in 2 centres within France. The PerQseal® + shal...
Detailed Description
The study shall not be blinded prior to, during or post the procedure. All patients undergoing an endovascular procedure requiring an arteriotomy created by 14 to 22 F sheaths, via the common femoral ...
Eligibility Criteria
Inclusion
- i. Over 18 years of age. ii. Subject is willing and able to provide appropriate study-specific informed consent, follow protocol procedures, and comply with follow-up visit requirements.
- iii. Clinically indicated for an endovascular procedure using a common femoral arteriotomy created by a 14 - 22 F sheath.
- General
Exclusion
- i. Severe acute non-cardiac systemic disease or terminal illness with a life expectancy of less than four months.
- ii. Evidence of systemic bacterial or cutaneous infection, including groin infection.
- iii. Known bleeding diathesis (including sever liver disease), definite or potential coagulopathy, platelet count \< 100,000/µl or patients on long term anticoagulants with an INR greater than 2 at time of procedure or known type II heparin-induced thrombocytopenia.
- iv. Previous groin surgery within the region of the ipsilateral access. v. Severe; claudication or peripheral vascular disease (e.g. Rutherford category 3 or greater or ABI \< 0.5), documented untreated iliac artery diameter stenosis \> 50% or previous bypass surgery/stent placement in the common femoral artery of ipsilateral limb.
- vi. Known allergy to any of the materials used in the PerQseal® + or PerQseal® Introducer (refer to Investigator's Brochure for materials list).
- vii. Subject has undergone a percutaneous procedure using a non-absorbable vascular closure device (excluding suture mediated) for haemostasis in the ipsilateral target leg.
- viii. Patients that have undergone a percutaneous procedure in the ipsilateral leg, within the previous 30 days.
- ix. Patients that have undergone a percutaneous procedure using an absorbable intravascular closure device for haemostasis, in the ipsilateral leg, within the previous 90 days.
- x. Evidence of arterial diameter stenosis \> 20% or anterior or circumferential calcification within 20 mm proximal or distal to target arteriotomy site based on pre-procedure CT angiography.
- xi. Females who are pregnant or lactating or in fertile period not taking adequate contraceptives. A pregnancy test may be performed.
- xii. Patients that have a lower extremity amputation from the ipsilateral or contralateral limb.
- xiii. Target puncture site is located in a vascular graft.
- Procedural
Key Trial Info
Start Date :
May 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2023
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05323877
Start Date
May 1 2022
End Date
April 1 2023
Last Update
April 12 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.